Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Fujisawa USA's clonidine injection

Executive Summary

Fujisawa USA's clonidine injection: Epidural clonidine NDA filed Aug. 7, company reports. The alpha-2 partial adrenergic agonist would be indicated for treatment of severe pain in cancer patients when used together with opiate-based drugs. Fujisawa USA has been granted orphan drug status for clonidine for "continuous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to or unresponsive to intraspinal opiates alone"...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS026716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel